A Phase III Multicentre, Double Blind, Placebo-controlled, Parallel Group 52-week Study to Assess the Efficacy and Safety of 2 Dose Regimens of Lyophilised CDP870 as Additional Medication to Methotrexate in the Treatment of Signs and Symptoms and Preventing Structural Damage in Patients With Active Rheumatoid Arthritis Who Have an Incomplete Response to Methotrexate.

Trial Profile

A Phase III Multicentre, Double Blind, Placebo-controlled, Parallel Group 52-week Study to Assess the Efficacy and Safety of 2 Dose Regimens of Lyophilised CDP870 as Additional Medication to Methotrexate in the Treatment of Signs and Symptoms and Preventing Structural Damage in Patients With Active Rheumatoid Arthritis Who Have an Incomplete Response to Methotrexate.

Completed
Phase of Trial: Phase III

Latest Information Update: 17 Feb 2017

At a glance

  • Drugs Certolizumab pegol (Primary) ; Methotrexate
  • Indications Rheumatoid arthritis
  • Focus Registrational; Therapeutic Use
  • Acronyms RAPID-1; RAPID1
  • Sponsors UCB
  • Most Recent Events

    • 06 Nov 2013 Post-hoc results comparing different clinical indicators in predicting clinical response presented at the 16th Annual European Conference of the International Society for Pharmacoeconomics and Outcomes Research.
    • 10 May 2011 Results from a post hoc analysis of this trial (RAPID-1) have been published in the Journal of Rheumatology according to a UCB media release; results were also reported in the media release.
    • 17 Oct 2009 Results presented at the 2009 Annual Scientific Meeting of the American College of Rheumatology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top